ZOVIRAX
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOVIRAX is an injectable antiviral small molecule approved in 1982 for viral infections, likely herpes simplex virus (HSV) and varicella-zoster virus (VZV) based on historical context. The drug is administered intravenously and represents a foundational therapy in antiviral treatment.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), indicating a mature asset with declining team investment and transition focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZOVIRAX offers limited career advancement in innovation but strong opportunities in managed care, market access, and lifecycle management for professionals seeking to optimize mature asset portfolios. This role is ideal for specialists in generic transition strategy, hospital formulary management, and competitive repositioning rather than novel drug development.
Medical Science Liaison
Worked on ZOVIRAX at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.